Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal Calcium Absorption
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Calcichew D3Drug: Noncarbonated Water
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT02338713
A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants
Phase 3
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: TVP-1012 1mg
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 222
- Registration Number
- NCT02337764
Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma
Phase 2
Completed
- Conditions
- Colorectal Carcinoma
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 164
- Registration Number
- NCT02337946
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
Phase 3
Completed
- Conditions
- Parkinson's Disease
- Interventions
- Drug: PlaceboDrug: TVP-1012
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 244
- Registration Number
- NCT02337725
Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants
Phase 1
Completed
- Conditions
- Dose Finding Study
- Interventions
- Drug: TAK-137Drug: Placebo
- First Posted Date
- 2015-01-09
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 47
- Registration Number
- NCT02334982
A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus and Microalbuminuria
- Interventions
- First Posted Date
- 2015-01-07
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 415
- Registration Number
- NCT02332824
A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: SYR-472Drug: Placebo
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 240
- Registration Number
- NCT02324569
A Phase 1, Single and Multiple Dose Study of TAK-137
Phase 1
Withdrawn
- Conditions
- Healthy Japanese Adult Male
- Interventions
- Drug: TAK-137 5 mg tablet, TAK-137 placebo tabletDrug: TAK-137 5mg tablet, TAK-137 placebo tabletDrug: TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2015-11-26
- Lead Sponsor
- Takeda
- Registration Number
- NCT02322606
Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults
Phase 1
Completed
- Conditions
- Influenza Infection
- Interventions
- Drug: Subcutaneous injection of TAK-850Drug: Intramuscular injection of TAK-850
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 110
- Registration Number
- NCT02313155
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 706
- Registration Number
- NCT02312258
- Locations
- 🇧🇷
Clinica Sao Germano, Sao Paulo, Brazil
🇺🇸North County Oncology Medical Clinic Inc, Oceanside, California, United States
🇦🇷Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC), Buenos Aires, Ciudad Autonoma De BuenosAires, Argentina
© Copyright 2025. All Rights Reserved by MedPath